Doxorubicin News and Research

RSS

Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.

Scientists assemble carbon nanotubes in a new way to deliver cancer drugs

Fundamental science often finds applications beyond its original focus. Previously, scientists found applications for small diameter carbon nanotube porins in energy technology.

29 Jan 2022

Engineering hairy cellulose nanocrystals to capture chemotherapy drugs

Millions of people around the globe are affected by cancer each year; more than 39% of men and women are diagnosed with cancer during their lifetime.

7 Jan 2022

New engineered nanomaterials help capture chemotherapy drugs to avoid tissue damage

Standard chemotherapies may efficiently kill cancer cells, but they also pose significant risks to healthy cells, resulting in secondary illness and a diminished quality of life for patients. To prevent the previously unavoidable damage, researchers, led by Penn State, have developed a new class of nanomaterials engineered to capture chemotherapy drugs before they interact with healthy tissue.

6 Jan 2022

Genomic variant may help predict which patients will experience chemotherapy-induced cardiotoxicity

A team of investigators have discovered a genomic variant that may help clinicians predict which patients will experience cardiotoxicity from a widely used chemotherapy drug, according to a Northwestern Medicine study published in Circulation.

3 Jan 2022

Protein can protect the heart from damage following cancer treatment

Cancer treatment can be tough on the body, but for the patient to survive the cancer, it's often necessary to go through with the treatment anyway.

13 Dec 2021

Ibrutinib plus standard chemotherapy effective in younger patients with diffuse large B-cell lymphoma

Younger patients with specific genetic subtypes of non-GCB DLBCL, called MCD and N1, had an exceptional response to the treatment combination.

5 Nov 2021

New system created for targeted delivery of anti-cancer drugs

RUDN University and Shahid Beheshti University (SBU) chemist together with colleagues from Iran created a system for targeted delivery of anti-cancer drugs.

27 Oct 2021

Elevated allostatic load may impact treatment completion and breast cancer survival outcomes

Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival rate in patients with lymph node-positive or high-risk lymph node-negative HER2-negative breast cancer, according to results presented at the 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held online October 6-8, 2021.

6 Oct 2021

Cardiotoxic effects of common chemotherapy drug could be prevented

Harmful side effects from a common chemotherapy drug could be the result of a single mutation, according to a study published in Cell Stem Cell.

24 Sep 2021

DNMT2/TRDMT1 gene knockout may potentiate adverse effects related to drug-induced senescence

Aging-US published "The lack of functional DNMT2/TRDMT1 gene modulates cancer cell responses during drug-induced senescence" which reported that cellular senescence may be a side effect of chemotherapy and other anti-cancer treatments that may promote inflammation and paracrine secondary senescence in healthy tissues.

31 Aug 2021

Studies shed light on the versatility, precision, and sensitivity of quantitative analytical tools

Three independent studies in the Journal of Pharmaceutical Analysis explore the potential uses and applications of quantitative analytical tools in the characterization and quality assessment of biological and medicinal compounds.

19 Aug 2021

Anti-cancer prodrug can benefit cancer patients

Unlike conventional cancer drugs that attack and kill cancer cells directly, anti-cancer immunotherapy, which kills cancer cells by strengthening the body's immunity, is a novel type of cancer treatment currently attracting increased attention. Unfortunately, a minority of cancer patients who have some degree of pre-existing immunity only benefit from anti-cancer immunotherapy.

28 Jun 2021

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.

18 Jun 2021

The Role of Nanoparticles for Drug Delivery

In this interview, Mark Bumiller, Technology Manager at Entegris talks to News Medical Life Sciences about the role nanoparticles can play in drug delivery.

From Entegris, Inc. 15 Jun 2021

Cdkn1a transcript variant 2 is selectively elevated during natural aging across mouse tissues

Aging published "Cdkn1a transcript variant 2 is a marker of aging and cellular senescence" which reported that cellular senescence is a cell fate response characterized by a permanent cell cycle arrest driven primarily the by cell cycle inhibitor and tumor suppressor proteins p16Ink4a and p21Cip1/Waf1.

3 Jun 2021

Lengthy treatment with low-dose 6-mercaptopurine inhibits resistant triple-negative breast cancer cells

The cover for issue 7 of Oncotarget features Figure 5, "SUM149-MA cells surviving a 6-MP treatment are sensitive to chemotherapeutic drugs," published in "Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine" by Singh, et al. which reported that the authors have reported that a lengthy treatment with low-dose 6-mercaptopurine, a clinically useful anti-inflammatory drug, inhibits such resistant cells.

19 May 2021

Doxorubicin News and Research

Scientists assemble carbon nanotubes in a new way to deliver cancer drugs

Engineering hairy cellulose nanocrystals to capture chemotherapy drugs

New engineered nanomaterials help capture chemotherapy drugs to avoid tissue damage

Genomic variant may help predict which patients will experience chemotherapy-induced cardiotoxicity

Protein can protect the heart from damage following cancer treatment

Ibrutinib plus standard chemotherapy effective in younger patients with diffuse large B-cell lymphoma

New system created for targeted delivery of anti-cancer drugs

Elevated allostatic load may impact treatment completion and breast cancer survival outcomes

Cardiotoxic effects of common chemotherapy drug could be prevented

DNMT2/TRDMT1 gene knockout may potentiate adverse effects related to drug-induced senescence

Studies shed light on the versatility, precision, and sensitivity of quantitative analytical tools

Anti-cancer prodrug can benefit cancer patients

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

The Role of Nanoparticles for Drug Delivery

Cdkn1a transcript variant 2 is selectively elevated during natural aging across mouse tissues

Lengthy treatment with low-dose 6-mercaptopurine inhibits resistant triple-negative breast cancer cells

Review helps understand the mechanisms of R-CHOP resistance in diffuse large B-cell lymphoma

Researchers study the digestion process of drug-loaded DNA nanostructures in real time

New glioma-targeted nano-therapeutic offers a potential treatment for glioblastomas

New gut microbiome-based approach may have translational potential for cancer immunotherapy

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News